<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    proprietary blood collection device

    Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature

    Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature. Findings Suggest Blood Collection Device Simplifies Specimen Collection and Transport While Maintaining Accuracy of Diagnostic Test Results

    Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited)

    Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million.

    Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test

    Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test.

    Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer

    Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer.

    Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine

    Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine.

    Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

    Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).

    HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization

    HiberCell today announced an agreement with Biodesix, Inc. to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs.

    Purdue partners with Colorado company to offer rapid testing for students ahead of spring 2021 semester

    Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester.

    Biodesix Announces Third Quarter 2020 Results and Provides Corporate Update

    Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the third quarter ended September 30, 2020 and provided a corporate update.

    Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making

    Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a firstin-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS) policy statement on the early detection of lung cancer.